U.S. markets closed

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.6450+0.0100 (+1.57%)
At close: 8:00AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6350
Open0.6450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6450 - 0.6450
52 Week Range0.3280 - 0.7250
Volume58
Avg. Volume83
Market Cap23.783M
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Canntab Announces the Early Exercise of $1,259,250 Warrants
      CNW Group

      Canntab Announces the Early Exercise of $1,259,250 Warrants

      Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of 1,679,000 warrants into common shares (the "Warrants"). The Warrants were issued in the final week of May and each Warrant was exercised into 1 common share in the capital of the Company at $0.75. T

    • Canntab Mourns the Loss of Co-Founder
      CNW Group

      Canntab Mourns the Loss of Co-Founder

      Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick, the Company's Co-Founder, Director and President. After a long and difficult 15 month battle, Jeff succumbed to his lung cancer at the young age of 54 years.

    • Canntab Receives Export License Approval from Health Canada
      PR Newswire

      Canntab Receives Export License Approval from Health Canada

      Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.